Zentiva is a pharmaceutical group, specialized in the development, manufacturing and marketing of branded equivalents. It holds the leading positions in the Czech and Slovak markets and is among the pharmaceutical players within the Central and Eastern European (CEE) region. The Czech Republic, the Slovak Republic, Poland and the Russian Federation are currently the most important markets for the Zentiva group. The company is also developing its business in many other countries in Central and Eastern Europe. The company´s product range consists of almost 270 products in some 500 pharmaceutical presentations. While Zentiva addresses a large number of therapeutic areas, it focuses, in particular, on the treatment of cardiovascular disorders, inflammatory conditions, pain, infections and diseases of the central nervous system and the gastrointestinal and urinary tracts. It also has a growing consumer healthcare portfolio comprising over-the-counter (OTC) medicines and dietary supplements.
Dolni Mecholupy, U kabelovny 130
Prague; The City of Prague; Postal Code: 10237
Contact Details: Purchase the Zentiva k.s. report to view the information.
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.Request a demo of the EMIS service
To view more information, Request a demonstration of the EMIS service